The agreement with Pfizer is worth up to $1 billion plus tiered royalties on sales after that, the company said Friday. The transaction is due to complete in the third quarter.
AstraZeneca appoints new EVP of BioPharmaceuticals R&D europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
July 28 (Reuters) - AstraZeneca (AZN.L) said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer's (PFE.N) early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales, as the British drugmaker bets on new genetic therapies. The British company also said Sharon Barr, head of research and development at Alexion, would